A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

NCT05692180 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Benralizumab
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]